EnChannel Medical, a company specializing in cardiac electrophysiology, began a deal to acquire the AcQMap high-resolution imaging and mapping platform assets from Acutus Medical.

The deal includes substantive intellectual property, quality and regulatory documentation, clinical data, a limited number of AcQMap systems, and associated catheter devices for research and development purposes. The acquisition bolsters EnChannel’s portfolio with second- and third-gen non-contact mapping (NCM) technologies, which form a foundation for full-chamber atrial fibrillation (AFib) mapping.

NCM reconstructs full-chamber electrical activity from cardiac signals sensed by electrodes placed in the atrial chamber cavity. It provides a single-beat depiction of activation over the whole atrial chamber at every instance of time, improving mapping efficiency and preserving dynamic patterns of regular and complex, irregular rhythms.

AcQMap is a second-gen NCM platform that advanced beyond first-gen voltage-to-voltage mapping—pioneered by Endocardial Solutions, now part of Abbott—and provided spatial resolution and accuracy using voltage-to-charge-density mapping.

EnChannel’s Action Potential Mapping is a third-gen NCM tech breakthrough, with accurate reconstruction of depolarization and repolarization dynamics. Action Potential Mapping approaches the real nature of cardiac conduction and allows understanding of the mechanisms that initiate and maintain AFib.

“This strategic acquisition accelerates our mission to visualize and treat AF with unprecedented efficiency and precision,” said Jun Feng, CEO of EnChannel Medical. “By building on prior advancements and leveraging our proprietary technologies, we are shaping the future of persistent AF diagnosis and treatment.”

“Many of us at EnChannel had essential roles in developing all three generations of non-contact mapping,” said Graydon Beatty, CSO of EnChannel Medical. “Each generation informed and enabled the next one; from reproduction of the cardiac signal in the first; to resolving the physical electric source of the signal in the second; and now culminating in reconstruction of the physiologic action potential in the third, revealing the actual nature of cardiac conduction dynamics. This acquisition unites our history of requisite methods and resources across the generations, and advances a hybrid workflow of all modes of navigation, mapping, and visualization. We are poised and resolved to establish an electrophysiology ecosystem that uncovers the mechanisms of AF, optimizes patient-specific treatment, and improves clinical outcomes in persistent AF.”